Amir M. Zaid, Eslam Eid, Sherihan I. Gouda, M. Aboelnaga, R. Abdelsalam, A. M. Elbeltagy, Doaa M. Khedr, M. Shetiwy, I. Elzahaby, M. Hafez
{"title":"Evaluation of Risk Factors for Malignancy in Patients With Thyroid Nodules","authors":"Amir M. Zaid, Eslam Eid, Sherihan I. Gouda, M. Aboelnaga, R. Abdelsalam, A. M. Elbeltagy, Doaa M. Khedr, M. Shetiwy, I. Elzahaby, M. Hafez","doi":"10.14740/jem770","DOIUrl":"https://doi.org/10.14740/jem770","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43427268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sedentary Lifestyle Attenuates Positive Metabolic Effect of Regular Physical Exercise","authors":"A. Isayeva, M. Vovchenko, O. Petyunina","doi":"10.14740/jem797","DOIUrl":"https://doi.org/10.14740/jem797","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42673042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Kusunoki, F. Hisano, Shinichi Matsuda, N. Wakazono, K. Tsutsumi, T. Miyata
Background: Selective inhibitors of sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reported to improve glucose metabolism, lipid metabolism and liver dysfunction in patients with type 2 diabetes mellitus. However, few studies have investigated if the effects of this class of drugs vary according to the age of the patients. This study was conducted to determine the influence of age on the effects of SGLT2 inhibitors in Japanese patients with diabetes mellitus. Methods: SGLT2 inhibitors were administered for 6 months to 199 patients with type 2 diabetes mellitus. The body weight, body mass index (BMI), visceral fat area, serum glucose, hemoglobin A1c (HbA1c), blood lipid levels, serum uric acid, liver function parameters, and bone mineral density were measured before and after 6 months of treatment, and regression analysis was performed to examine the relationship between age and the effects of SGLT2 inhibitors. Results: The results of the regression analysis showed that the effects of SGLT2 inhibitors on the serum levels of high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), and γ-glutamyl transpeptidase (γ-GTP) were influenced by the patient age. The effect of SGLT2 inhibitors in increasing the serum HDL-C was more pronounced in older patients. There was an interaction between age and the baseline levels of the serum AST and γ-GTP; reductions of the serum AST and γ-GTP levels by SGPLT2 inhibitors were more pronounced in younger patients with higher baseline levels of these parameters, but not pronounced in aged patients. Conclusions: The effects of SGLT2 inhibitor treatment on the serum HDL-C, AST and γ-GTP levels were affected by the patient age: their beneficial effect on the serum HDL-C increased with the patient age and their effects in reducing the serum AST and γ-GTP decreased with the patient age. The effects of SGLT2 inhibitor treat-ment on the blood glucose and serum HbA1c were not affected by the patient age, suggesting that SGLT2 inhibitors can be used as antidiabetic drugs in patients over a wide age range, from the young to the elderly.
{"title":"Influence of Age on the Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients With Type 2 Diabetes Mellitus","authors":"M. Kusunoki, F. Hisano, Shinichi Matsuda, N. Wakazono, K. Tsutsumi, T. Miyata","doi":"10.14740/jem799","DOIUrl":"https://doi.org/10.14740/jem799","url":null,"abstract":"Background: Selective inhibitors of sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reported to improve glucose metabolism, lipid metabolism and liver dysfunction in patients with type 2 diabetes mellitus. However, few studies have investigated if the effects of this class of drugs vary according to the age of the patients. This study was conducted to determine the influence of age on the effects of SGLT2 inhibitors in Japanese patients with diabetes mellitus. Methods: SGLT2 inhibitors were administered for 6 months to 199 patients with type 2 diabetes mellitus. The body weight, body mass index (BMI), visceral fat area, serum glucose, hemoglobin A1c (HbA1c), blood lipid levels, serum uric acid, liver function parameters, and bone mineral density were measured before and after 6 months of treatment, and regression analysis was performed to examine the relationship between age and the effects of SGLT2 inhibitors. Results: The results of the regression analysis showed that the effects of SGLT2 inhibitors on the serum levels of high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), and γ-glutamyl transpeptidase (γ-GTP) were influenced by the patient age. The effect of SGLT2 inhibitors in increasing the serum HDL-C was more pronounced in older patients. There was an interaction between age and the baseline levels of the serum AST and γ-GTP; reductions of the serum AST and γ-GTP levels by SGPLT2 inhibitors were more pronounced in younger patients with higher baseline levels of these parameters, but not pronounced in aged patients. Conclusions: The effects of SGLT2 inhibitor treatment on the serum HDL-C, AST and γ-GTP levels were affected by the patient age: their beneficial effect on the serum HDL-C increased with the patient age and their effects in reducing the serum AST and γ-GTP decreased with the patient age. The effects of SGLT2 inhibitor treat-ment on the blood glucose and serum HbA1c were not affected by the patient age, suggesting that SGLT2 inhibitors can be used as antidiabetic drugs in patients over a wide age range, from the young to the elderly.","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49464107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Paz-Ibarra, D. Sueldo-Espinoza, Ronald Vicente Concha-Tamo, Vladimir Zamamé-Ramírez, Víctor Velásquez-Rimachi, M. Concepción-Zavaleta
{"title":"Pleuropericardial Compromise Associated With Graves’ Disease: A Systematic Review","authors":"J. Paz-Ibarra, D. Sueldo-Espinoza, Ronald Vicente Concha-Tamo, Vladimir Zamamé-Ramírez, Víctor Velásquez-Rimachi, M. Concepción-Zavaleta","doi":"10.14740/jem790","DOIUrl":"https://doi.org/10.14740/jem790","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47888218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Ashraf, M. S. Khan, S. S. Lone, M. H. Bhat, Samia Rashid, S. Majid, Haamid Bashir
{"title":"Implication of Leptin and Leptin Receptor Gene Variations in Type 2 Diabetes Mellitus: A Case-Control Study","authors":"R. Ashraf, M. S. Khan, S. S. Lone, M. H. Bhat, Samia Rashid, S. Majid, Haamid Bashir","doi":"10.14740/jem785","DOIUrl":"https://doi.org/10.14740/jem785","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42767411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Predictors of Antenatal Insulin Requirement in Women With Gestational Diabetes Mellitus: A Prospective Observational Cohort Study","authors":"Neelu Rajkumar Sontakke, Sweta Singh, Subarna Mitra, Kishore Behera, P. Mohanty","doi":"10.14740/jem793","DOIUrl":"https://doi.org/10.14740/jem793","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46148589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extreme Elevation of Alkaline Phosphatase in a Pregnancy Complicated by Uncontrolled Chronic Hypertension and Its Association With Placental Pathology","authors":"Ena Arora, Tracey Juron, A. Fuks, C. Salafia","doi":"10.14740/jem789","DOIUrl":"https://doi.org/10.14740/jem789","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47119072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Inhibitors of dipeptidyl peptidase-4 (DPP4) have been used for diabetic patients and there is debate around using the same DPP4 inhibitors as a potential source of treatment for severe corona-virus disease 2019 (COVID-19). The findings from individual stud-ies regarding the usage of DDP4 inhibitors on COVID infection are available but not reviewed and synthesized. Therefore, we aimed to conduct a systematic review to synthesize the findings regarding its effect on the COVID infection course and the outcome. Methods: We carried out an electronic search in Google Scholar and PubMed. We considered a study eligible if it was an original research study, published in English during the era of COVID-19 till Septem-ber 2021, and had provided information on the topic of DPP4 inhibi-tors and COVID infection followed by reviewing the full-text articles and summarizing their findings. Results: This review provided novel insights into the effect of DDP4 inhibitor users and its effect on COVID-19 patients. Overall, litera-ture is scarce on the effect of DDP4 inhibitors on COVID severity and we found mixed results regarding the DDP4 effects on disease sever-ity and mortality. The evidence is not consistent currently as some of the studies supported the role of DDP4 inhibitor, while other stud-ies provided contradictory findings. UK population data published in 2021 with 2.5 million diabetic patients found no evidence to support a protective effect of DDP inhibitors on morbidity and mortality related to COVID-19. Conclusion: The findings of the review reveal that there is some ben-efit of the usage of DDP4 inhibitors on COVID-19 morbidity and mortality. However, we highly recommend replicating the studies in different contexts before making any strong recommendations. Furthermore, the results need to be interpreted cautiously due to the scarcity of literature on the role of DDP4 inhibitors among diabetic patients with COVID-19.
{"title":"Understanding the Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: Findings From a Systematic Review","authors":"S. Aldukhi, M. Batais","doi":"10.14740/jem767","DOIUrl":"https://doi.org/10.14740/jem767","url":null,"abstract":"Background: Inhibitors of dipeptidyl peptidase-4 (DPP4) have been used for diabetic patients and there is debate around using the same DPP4 inhibitors as a potential source of treatment for severe corona-virus disease 2019 (COVID-19). The findings from individual stud-ies regarding the usage of DDP4 inhibitors on COVID infection are available but not reviewed and synthesized. Therefore, we aimed to conduct a systematic review to synthesize the findings regarding its effect on the COVID infection course and the outcome. Methods: We carried out an electronic search in Google Scholar and PubMed. We considered a study eligible if it was an original research study, published in English during the era of COVID-19 till Septem-ber 2021, and had provided information on the topic of DPP4 inhibi-tors and COVID infection followed by reviewing the full-text articles and summarizing their findings. Results: This review provided novel insights into the effect of DDP4 inhibitor users and its effect on COVID-19 patients. Overall, litera-ture is scarce on the effect of DDP4 inhibitors on COVID severity and we found mixed results regarding the DDP4 effects on disease sever-ity and mortality. The evidence is not consistent currently as some of the studies supported the role of DDP4 inhibitor, while other stud-ies provided contradictory findings. UK population data published in 2021 with 2.5 million diabetic patients found no evidence to support a protective effect of DDP inhibitors on morbidity and mortality related to COVID-19. Conclusion: The findings of the review reveal that there is some ben-efit of the usage of DDP4 inhibitors on COVID-19 morbidity and mortality. However, we highly recommend replicating the studies in different contexts before making any strong recommendations. Furthermore, the results need to be interpreted cautiously due to the scarcity of literature on the role of DDP4 inhibitors among diabetic patients with COVID-19.","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46017521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. M. Martins, Catarina Maia, J. Miguens, D. Presa
{"title":"Cushing’s Disease of Unknown Etiology: A Clinical Case Report","authors":"J. M. Martins, Catarina Maia, J. Miguens, D. Presa","doi":"10.14740/jem784","DOIUrl":"https://doi.org/10.14740/jem784","url":null,"abstract":"","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49398764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Yurchenko, D. Krenytska, Olesya Kalmukova, N. Raksha, T. Halenova, T. Vovk, O. Savchuk, Mycola Dzerzhynsky, L. Ostapchenko, V. Tomchuk
Background: Overweight and obesity have become a global epidemic that presents a risk to health. Serotonin is involved in the regulation of many important functions of the body as in the periphery (as a hormone), as well as in the central nervous system as a neurotransmitter, which can be involved in central mechanisms that control food intake. The present work aimed to study the features of serotonin metabolism functioning under the effect of the kidney beans ( Phaseolus vulgaris ) pods extract in experimental obesity, which was induced by the consumption of high-calorie diet. Phaseolus vulgaris is the plant that possesses plenty of curative and therapeutic properties in particular for the treatment of diabetes mellitus, obesity, and cardiovascular diseases. It has been known that plant extracts, unlike synthetic drugs, can be used practically without toxic effects. Methods: Experiments were carried out on four groups of white nonlinear male rats (10 rats per group) during a 10-week period. Studies of the serotonergic system functioning were performed using ion-exchange chromatography, spectrofluorimetric and spectrophotometric methods. Results: The consumption of kidney beans ( Phaseolus vulgaris ) pods extract has a therapeutic effect on the obesity development in rats, as evidenced by changes in the functioning of the central and peripheral serotonergic systems. Tryptophan and serotonin levels have increased in duodenum mucosa compared to the obese rats, also had shown an increase of the serotonin synthesis enzymes activity (tryptophan hydroxylase and tryptophan decarboxylase) and a simultaneous decrease in the activity of monoamine oxidase. Central tryptophan and serotonin levels, as well as the activity of enzymes of the serotonin synthesis have increased compared to the obese rats while a simultaneous decrease in the activity of monoamine oxidase was observed. Conclusions: The obtained results indicated a therapeutic effect of the kidney beans ( Phaseolus vulgaris ) pods extract on the dysfunction of the serotonergic system under obesity development. J Endocrinol Metab. 2021;11(5):123-133 doi: https://doi.org/10.14740/jem650
{"title":"The Kidney Beans (Phaseolus vulgaris) Pods Extract Affects the Central and Peripheral Serotonergic Systems in Rats With High-Calorie Diet-Induced Obesity","authors":"A. Yurchenko, D. Krenytska, Olesya Kalmukova, N. Raksha, T. Halenova, T. Vovk, O. Savchuk, Mycola Dzerzhynsky, L. Ostapchenko, V. Tomchuk","doi":"10.14740/jem650","DOIUrl":"https://doi.org/10.14740/jem650","url":null,"abstract":"Background: Overweight and obesity have become a global epidemic that presents a risk to health. Serotonin is involved in the regulation of many important functions of the body as in the periphery (as a hormone), as well as in the central nervous system as a neurotransmitter, which can be involved in central mechanisms that control food intake. The present work aimed to study the features of serotonin metabolism functioning under the effect of the kidney beans ( Phaseolus vulgaris ) pods extract in experimental obesity, which was induced by the consumption of high-calorie diet. Phaseolus vulgaris is the plant that possesses plenty of curative and therapeutic properties in particular for the treatment of diabetes mellitus, obesity, and cardiovascular diseases. It has been known that plant extracts, unlike synthetic drugs, can be used practically without toxic effects. Methods: Experiments were carried out on four groups of white nonlinear male rats (10 rats per group) during a 10-week period. Studies of the serotonergic system functioning were performed using ion-exchange chromatography, spectrofluorimetric and spectrophotometric methods. Results: The consumption of kidney beans ( Phaseolus vulgaris ) pods extract has a therapeutic effect on the obesity development in rats, as evidenced by changes in the functioning of the central and peripheral serotonergic systems. Tryptophan and serotonin levels have increased in duodenum mucosa compared to the obese rats, also had shown an increase of the serotonin synthesis enzymes activity (tryptophan hydroxylase and tryptophan decarboxylase) and a simultaneous decrease in the activity of monoamine oxidase. Central tryptophan and serotonin levels, as well as the activity of enzymes of the serotonin synthesis have increased compared to the obese rats while a simultaneous decrease in the activity of monoamine oxidase was observed. Conclusions: The obtained results indicated a therapeutic effect of the kidney beans ( Phaseolus vulgaris ) pods extract on the dysfunction of the serotonergic system under obesity development. J Endocrinol Metab. 2021;11(5):123-133 doi: https://doi.org/10.14740/jem650","PeriodicalId":15712,"journal":{"name":"Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49581303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：